Evidence map›Paper›PMID 42400372›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Structure-guided discovery and evaluation of an EGFR L858R-targeting peptide with antiproliferative activity against ovarian cancer cells.

Yinxing Zhu, Hanying Wu, Xiaohao Liu, Rui Li, Min Jiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yinxing ZhuDepartment of Traditional Chinese Medicine, Taizhou Affiliated Hospital of Nanjing University of Chinese Medicine, Taizhou, China.
Hanying WuDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Xiaohao LiuDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Rui LiDepartment of Surgery, Hai 'an Hospital of Traditional Chinese Medicine, Nantong, China.
Min JiangDepartment of Rehabilitation, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

EGFR L858R is an activating mutation associated with aberrant EGFR signalling, and molecules capable of recognising this mutant remain of research interest. In this study, a virtual peptide library containing 59 319 heptapeptides was screened against the EGFR L858R crystal structure, leading to the identification of four peptides with favourable predicted binding ability. Among them, Peptide-1 showed the strongest binding affinity in MST assays (

Indexed as

Antineoplastic AgentsDrug DiscoveryOvarian NeoplasmsPeptidesProtein Kinase InhibitorsCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorErbB ReceptorsFemaleHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsEGFR protein, humanErbB ReceptorsPeptidesProtein Kinase InhibitorsEGFR L858Rmolecular dockingovarian cancerpeptidevirtual screening

Identifiers

PMID42400372
PMCPMC13348117

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.